Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma

NCT03152708 is registered in ClinicalTrials.gov with CANbridge Life Sciences Ltd. as lead sponsor.

NCT NCT03152708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03152708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma
Lead sponsor
CANbridge Life Sciences Ltd.
Phase
Observational
Overall status
Unknown status
Start date
November 1, 2017
Completion date
December 31, 2017
Enrollment
62 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma